William Blair Has Positive Outlook of SRPT FY2024 Earnings

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at William Blair lifted their FY2024 earnings per share estimates for Sarepta Therapeutics in a report issued on Tuesday, January 21st. William Blair analyst S. Corwin now expects that the biotechnology company will earn $2.73 per share for the year, up from their prior forecast of $2.03. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.92 EPS and FY2025 earnings at $11.70 EPS.

Several other equities analysts also recently issued reports on SRPT. Robert W. Baird decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, January 14th. Finally, Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $178.71.

Sarepta Therapeutics Trading Down 2.2 %

NASDAQ SRPT opened at $116.46 on Thursday. The firm’s fifty day moving average price is $122.17 and its 200 day moving average price is $128.47. Sarepta Therapeutics has a 12 month low of $102.15 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market capitalization of $11.12 billion, a price-to-earnings ratio of 93.17 and a beta of 0.77.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after purchasing an additional 543,143 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Sarepta Therapeutics by 32.3% during the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after buying an additional 665,087 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Sarepta Therapeutics by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after buying an additional 44,306 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Sarepta Therapeutics by 9.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after buying an additional 63,437 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $79,425,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity

In other news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.